

# Reporting checklist for protocol of a systematic review and meta analysis.

Based on the PRISMA-P guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the PRISMA-Reporting guidelines, and cite them as:

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.

Reporting Item			Page Number
Title			
Identification	<a href="#">#1a</a>	Identify the report as a protocol of a systematic review	1
Update	<a href="#">#1b</a>	If the protocol is for an update of a previous systematic review, identify as such	n/a
Registration			
	<a href="#">#2</a>	If registered, provide the name of the registry (such as PROSPERO) and registration number	2
Authors			
Contact	<a href="#">#3a</a>	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contribution	<a href="#">#3b</a>	Describe contributions of protocol authors and identify the	7

guarantor of the review

## Amendments

<a href="#">#4</a>	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	4
--------------------	---	---

## Support

Sources	<a href="#">#5a</a>	Indicate sources of financial or other support for the review	n/a
Sponsor	<a href="#">#5b</a>	Provide name for the review funder and / or sponsor	n/a
Role of sponsor or funder	<a href="#">#5c</a>	Describe roles of funder(s), sponsor(s), and / or institution(s), if any, in developing the protocol	n/a

## Introduction

Rationale	<a href="#">#6</a>	Describe the rationale for the review in the context of what is already known	4
Objectives	<a href="#">#7</a>	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	4

## Methods

Eligibility criteria	<a href="#">#8</a>	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	4
Information sources	<a href="#">#9</a>	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	4
Search strategy	<a href="#">#10</a>	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	5
Study records - data management	<a href="#">#11a</a>	Describe the mechanism(s) that will be used to manage records and data throughout the review	5
Study records -	<a href="#">#11b</a>	State the process that will be used for selecting studies (such	5

selection process		as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	
Study records - data collection process	<a href="#">#11c</a>	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	5
Data items	<a href="#">#12</a>	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	5
Outcomes and prioritization	<a href="#">#13</a>	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	5
Risk of bias in individual studies	<a href="#">#14</a>	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	6
Data synthesis	<a href="#">#15a</a>	Describe criteria under which study data will be quantitatively synthesised	6
Data synthesis	<a href="#">#15b</a>	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I <sup>2</sup> , Kendall's $\tau$ )	6
Data synthesis	<a href="#">#15c</a>	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	6
Data synthesis	<a href="#">#15d</a>	If quantitative synthesis is not appropriate, describe the type of summary planned	6
Meta-bias(es)	<a href="#">#16</a>	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	6
Confidence in cumulative evidence	<a href="#">#17</a>	Describe how the strength of the body of evidence will be assessed (such as GRADE)	6

The PRISMA-P elaboration and explanation paper is distributed under the terms of the Creative Commons Attribution License CC-BY. This checklist was completed on 11. December 2021 using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)